No improvement in hemoglobin A1c following hepatiThis C viral clearance in patients with and without HIV

Abstract

HepatiThis C clearance with directly acting antivirals (DAAs) may be associated with acute decreases in hemoglobin A1c (HbA1c). We prospectively evaluated 251 chronic hepatiThis C virus (HCV)-infected subjects (31% human immunodefciency virus [HIV] positive) pre-and post-DAA therapy (median follow-up 28 months). Changes in HbA1c and glucose were minimal and did not differ by sustained virologic response (SVR), HIV, diabetes, or fbrosis. Following SVR, mean change in HbA1c was-0.022 ± 0.53%; however, total and low-density lipoprotein cholesterol increased signifcantly. Subjects with HIV had smaller transaminase reductions afer SVR. Sustained benefts in glycemia were not identifed following HCV clearance irrespective of HIV, diabetes, or fbrosis stage, whereas lipid alterations may warrant further investigation.